Proprotein Convertase Subtilisin Kexin Type 9 Inhibition for Autosomal Recessive Hypercholesterolemia-Brief Report.

doi:10.1161/ATVBAHA.116.307493

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Proprotein Convertase Subtilisin Kexin Type 9 Inhibition for Autosomal Recessive Hypercholesterolemia-Brief Report.

Arteriosclerosis, thrombosis, and vascular biology - 1 Aug 2016

Thedrez Aurélie, Sjouke Barbara, Passard Maxime, Prampart-Fauvet Simon, Guédon Alexis, Croyal Mikael, Dallinga-Thie Geesje, Peter Jorge, Blom Dirk, Ciccarese Milco, Cefalù Angelo B, Pisciotta Livia, Santos Raul D, Averna Maurizio, Raal Frederick, Pintus Paolo, Cossu Maria, Hovingh Kees, Lambert Gilles

Abstract excerpt

OBJECTIVE: Proprotein convertase subtilisin kexin type 9 (PCSK9) inhibitors lower low-density lipoprotein (LDL) cholesterol in the vast majority of patients with autosomal dominant familial hypercholesterolemia. Will PCSK9 inhibition with monoclonal antibodies, in particular alirocumab, be of therapeutic value for patients with autosomal recessive hypercholesterolemia (ARH)? APPROACH AND RESULTS: Primary...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Monoclonal, Humanized

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Anticholesteremic Agents

Share to Hydroxymethylglutaryl-CoA Reductase Inhibitors

Share to Hypercholesterolemia

Share to Hyperlipoproteinemia Type III

Share to Lovastatin

Share to Proprotein Convertase 9

Share to Serine Proteinase Inhibitors

Source

Open in PubMed

Identifiers

PMID: 27079874
DOI: 10.1161/ATVBAHA.116.307493

Genes

PCSK9

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Proprotein Convertase Subtilisin Kexin Type 9 Inhibition for Autosomal Recessive Hypercholesterolemia-Brief Report.PMID 27079874Read ↗

PCSK9: From discovery to therapeutic applications.Semantic proximity Read ↗

Characterization of Autosomal Dominant Hypercholesterolemia Caused by PCSK9 Gain of Function Mutations and Its Specific Treatment With Alirocumab, a PCSK9 Monoclonal Antibody.Semantic proximity Read ↗

Anti-PCSK9 antibodies for the treatment of heterozygous familial hypercholesterolemia: patient selection and perspectives.Semantic proximity Read ↗

Degradation of LDLR protein mediated by 'gain of function' PCSK9 mutants in normal and ARH cells.Semantic proximity Read ↗

Proprotein convertase subtilisin/kexin type 9 (PCSK9): lessons learned from patients with hypercholesterolemia.Semantic proximity Read ↗

Efficacy and Safety of Alirocumab in Patients With Autosomal Dominant Hypercholesterolemia Associated With Proprotein Convertase Subtilisin/Kexin Type 9 Gain-of-Function or Apolipoprotein B Loss-of-Function Mutations.Semantic proximity Read ↗

Homozygous Familial Hypercholesterolemia Patients With Identical Mutations Variably Express the LDLR (Low-Density Lipoprotein Receptor): Implications for the Efficacy of Evolocumab.Semantic proximity Read ↗

Elevated plasma PCSK9 level is equally detrimental for patients with nonfamilial hypercholesterolemia and heterozygous familial hypercholesterolemia, irrespective of low-density lipoprotein receptor defects.Semantic proximity Read ↗

Living the PCSK9 adventure: from the identification of a new gene in familial hypercholesterolemia towards a potential new class of anticholesterol drugs.Semantic proximity Read ↗

PCSK9 Mutations in Familial Hypercholesterolemia: from a Groundbreaking Discovery to Anti-PCSK9 Therapies.Semantic proximity Read ↗

Proprotein convertase subtilisin kexin 9: the third locus implicated in autosomal dominant hypercholesterolemia.Semantic proximity Read ↗

Proprotein convertase subtilisin/kexin type 9 inhibition: a new therapeutic mechanism for reducing cardiovascular disease risk.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.